Cytokinetics Incorporated  (CYTK)

News about Cytokinetics Incorporated

Cytokinetics: Reframing Obstacles into Opportunities for Growth
Jul 03 2024
In an impressive move, Cytokinetics, Incorporated (Nasdaq: CYTK) recently announced the provision of inducement grants to a select group of ...

Cytokinetics Advances Clinical Trials for Potential HCM Treatment, Aficamten, with Initiation of Phase 1 Study and En...
Jun 17 2024
Cytokinetics, Incorporated, a biopharmaceutical company focused on developing innovative treatments for cardiovascular diseases, has announced signifi...

Cytokinetics Strengthens Leadership Team with Inducement Grants to CFO Sung H. Lee
Jun 04 2024
Cytokinetics Grants Inducement Options and Units to CFO Sung H. LeeSOUTH SAN FRANCISCO, Calif., June 04, 2024 - Cytokinetics, Incorporated (Nasdaq: CY...

Cytokinetics Announces Successful Closure of $500 Million Public Offering of Common Stock
May 28 2024
SOUTH SAN FRANCISCO, Calif., May 28, 2024 - Cytokinetics, Incorporated (Nasdaq: CYTK), a leading biopharmaceutical company, is excited to an...

Cytokinetics Raises $500 Million in Public Offering, Bolstering Growth Prospects
May 23 2024
Cytokinetics Incorporated, a leading biopharmaceutical company based in South San Francisco, announced the successful pricing of a public of...

Cytokinetics Faces Financial Challenges with Proposed Public Offering of Common Stock
May 22 2024
SOUTH SAN FRANCISCO, Calif., May 22, 2024 - Cytokinetics, Incorporated (Nasdaq: CYTK) recently announced its plans for an underwritten publi...

Cytokinetics and Royalty Pharma Join Forces to Propel Specialty Cardiology Franchise
May 22 2024
In a significant move to support the commercial launch of their groundbreaking drug, Aficamten, and bolster their research and development (R&D) pipel...

Cytokinetics Demonstrates Statistically Significant and Clinically Meaningful Improvements in SEQUOIA-HCM Clinical Trial Results, Further Advancing Treatment for Hypertrophic Cardiomyopathy
May 13 2024
Cytokinetics, a leading biopharmaceutical company, recently presented the primary results of the SEQUOIA-HCM clinical trial at the European Society o...

Cytokinetics Announces Crucial Development in Pediatric Cardiology Treatment: Clinical Trial of Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy Now Open for Enrollment
May 08 2024
Cytokinetics, Incorporated, a pioneer in the biopharmaceutical industry, has recently announced that its CEDAR-HCM (Clinical Evaluation of Dosing with...

Cytokinetics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule
May 02 2024
SOUTH SAN FRANCISCO, Calif., May 02, 2024 - Cytokinetics, Incorporated (Nasdaq: CYTK) recently released news regarding the granting of stock...

Cytokinetics Incorporated shows promising signs of growth with reduced losses in fiscal year 2023
Nov 06 2023
The stock market can be a roller coaster ride, filled with highs and lows, but amidst the unpredictability, there are still reasons to be optimistic. ...

Cytokinetics Incorporated announced very difficult period, during the second quarter of 2023
Aug 04 2023
As a stock market journalist, it is my duty to interpret the financial results of various companies and provide insights to investors. Today, I will b...

Cytokinetics Incorporated*s Revenue Surges, but Elusive Profitability Remains a Challenge
May 08 2023
Cytokinetics Incorporated is a biopharmaceutical company that is dedicated to improving the lives of patients with serious medical conditions. The com...

Critical quarter for Cytokinetics Incorporated in the financial fourth quarter of 2022
May 08 2023

Critical three months for over the third quarter of 2022 earnings season
May 08 2023


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com